Related Experiment Video
Updated: Jan 22, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
Control of LDL Uptake in Human Cells by Targeting the LDLR Regulatory Long Non-coding RNA BM450697
Roslyn M Ray1, Anders Højgaard Hansen2, Sofie Slott2
1Center for Gene Therapy, City of Hope, Beckman Research Institute and Hematological Malignancy and Stem Cell Transplantation Institute, 1500 E. Duarte Rd., Duarte, CA, 91010, USA.
Insights
Targeting the BM450697 long non-coding RNA (lncRNA) with small interfering RNAs (siRNAs) can lower blood cholesterol by activating the LDL receptor. This approach offers a specific, long-term method for cholesterol regulation.
Area of Science:
- Biochemistry
- Molecular Biology
- Genetics
Background:
- Hypercholesterolemia, characterized by high blood cholesterol, is a major risk factor for heart disease.
- Elevated low-density lipoprotein (LDL) levels are causally linked to atherosclerotic cardiovascular disease (ASCVD).
- The liver's LDL receptor (LDLR) is crucial for removing cholesterol from the blood.
Purpose of the Study:
- To investigate the role of the lncRNA BM450697 as an epigenetic regulator of LDLR.
- To explore the therapeutic potential of targeting BM450697 for cholesterol reduction.
Main Methods:
- Interrogation of two small interfering RNAs (siRNAs) targeting the lncRNA BM450697.
- Assessment of both transcriptional and post-transcriptional effects of siRNA-mediated BM450697 repression.
- Conjugation of α-N-acetylgalactosamine (GalNAc) to siRNAs for targeted liver cell delivery.
Main Results:
- BM450697 acts as a local scaffold modulating LDLR transcription.
- siRNA-mediated repression of BM450697 leads to LDLR activation.
- GalNAc conjugation enhances liver cell targeting and cholesterol uptake.
Conclusions:
- Targeting the BM450697 lncRNA regulator of LDLR presents a specific and long-term strategy for blood cholesterol management.
- This approach may offer a novel therapeutic avenue for hypercholesterolemia and ASCVD prevention.
Abstract:
Hypercholesterolemia is a condition that is characterized by very high levels of cholesterol in the blood and is a major correlating factor with heart disease. Indeed, high levels of the low-density lipoprotein (LDL) have been causally linked to the development of atherosclerotic cardiovascular disease (ASCVD). A method to specifically reduce cholesterol in the blood in a long-term, stable manner could prove therapeutically relevant. Cholesterol is removed from the blood by the LDL receptor (LDLR) in the liver. Others and we have discovered that a long non-coding RNA (lncRNA; BM450697) functions as an endogenous epigenetic regulator of LDLR and that the repression of this lncRNA by the action of small interfering RNAs (siRNAs) results in the activation of LDLR. We found here, through the interrogation of two siRNAs that can target this lncRNA, both in a transcriptional and post-transcriptional manner, that BM450697 functions as a local scaffold for modulating LDLR transcription. Moreover, we found that conjugation of α-N-acetylgalactosamine (GalNAc) with two lncRNA-directed siRNAs allows for direct liver cell targeting of this lncRNA and functional enhanced uptake of cholesterol. Collectively, these data suggest that targeting the BM450697 lncRNA regulator of LDLR may result in a more specific, long-term, targeted approach to regulating cholesterol in the blood.
Related Concept Videos
Cis-regulatory Sequences
lncRNA - Long Non-coding RNAs
Drug Control Governance: Regulatory Bodies and Their Impact
RNA Polymerase II Accessory Proteins
RNA Splicing
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

